Despite ongoing vaccination efforts to prevent SARS‐CoV‐2 infections, treatment tools are still necessary to address the ongoing COVID‐19 pandemic. We report here that COVID‐HIGIV, a human immunoglobulin product for treatment of COVID‐19, provided a significant survival benefit in SARS‐CoV‐2 infected transgenic mice compared to controls. COVID‐HIGIV also has similar pharmacokinetic profiles in healthy and SARS‐CoV‐2 infected mice over time after intravenous administration, with identical or comparable Tmax, Cmax, AUC0‐∞ and Cl. AUC0‐last increased and mean residence time, T1/2, and Vd reduced in infected animals compared to healthy animals. These data suggest that COVID‐HIGIV may be an effective treatment for SARS‐CoV‐2 infection when given early after exposure.
Loading....